Ryo Amagai
Overview
Explore the profile of Ryo Amagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamazaki E, Fujimura T, Takahashi-Watanabe M, Amagai R, Tamabuchi E, Oka K, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004774
: Cutaneous squamous cell carcinoma (cSCC) is a common cutaneous malignancy with diverse etiologies, including actinic keratosis, burns, and hidradenitis suppurativa (HS). : We reviewed 237 cases diagnosed as cSCC...
2.
Ikawa T, Yamazaki E, Amagai R, Kambayashi Y, Sekine M, Takahashi T, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858106
Background: Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin's lymphoma that primarily affects the skin, rich in hyaluronic acid (HA). HA is a component of the extracellular matrix in...
3.
Yoshida-Akai S, Fujimura T, Amagai R, Kambayashi Y, Hashimoto A, Terui H, et al.
Case Rep Oncol
. 2024 Oct;
17(1):1050-1054.
PMID: 39474537
Introduction: Basal cell carcinoma (BCC) is a common skin cancer that rarely metastasizes but can deeply infiltrate local tissues. The small number of unresectable BCC cases makes it difficult to...
4.
Okuda-Hiwatashi S, Amagai R, Fujimura T, Kambayashi Y, Watanabe-Takahashi M, Yamazaki E, et al.
J Clin Med
. 2024 Sep;
13(18).
PMID: 39337055
: Nivolumab plus ipilimumab (nivo/ipi) combination therapy is highly effective in treating advanced melanoma, but serious immune-related adverse events (irAEs) are prevalent. The overall response rate (ORR) of the BRAF...
5.
Yamazaki E, Fujimura T, Takahashi-Watanabe M, Tada S, Kitayama C, Amagai R, et al.
Br J Dermatol
. 2024 Aug;
192(1):167-169.
PMID: 39215562
No abstract available.
6.
Takahashi-Watanabe M, Fujimura T, Amagai R, Yamazaki E, Tamabuchi E, Akai S, et al.
Eur J Dermatol
. 2024 Aug;
34(4):442-444.
PMID: 39193688
No abstract available.
7.
Muto Y, Kambayashi Y, Kato H, Mizuhashi S, Ito T, Maekawa T, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123482
Background: Adjuvant therapy has improved the clinical prognosis for postoperative melanoma patients. However, the long-term efficacy of this therapy on the melanoma acral and mucosal subtypes has not been fully...
8.
Amagai R, Fujimura T, Hashimoto A, Yoshida S, Asano Y
Case Rep Oncol
. 2024 Jul;
17(1):681-685.
PMID: 39015640
Introduction: Capicua transcriptional repressor (CIC)-DUX4 rearranged sarcoma is a subtype of CIC-rearranged sarcomas composed of undifferentiated Wilms' tumor 1 (WT1), CD99 round cells with recurrent CIC gene rearrangement. The diagnosis...
9.
Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, et al.
Br J Dermatol
. 2024 Jun;
191(5):691-697.
PMID: 38833158
Background: Anti-programmed cell death 1 antibodies (PD-1 Abs) are widely used for advanced melanoma, but information on the efficacy of anti-PD-1 Abs is limited in the Asian population. There remains...
10.
Takahashi-Watanabe M, Fujimura T, Amagai R, Ohuchi K, Yamazaki E, Tamabuchi E, et al.
J Dermatol
. 2024 Apr;
51(11):1500-1503.
PMID: 38629702
Cutaneous squamous cell carcinoma (cSCC) arising from radiation dermatitis has a higher risk of metastasis than conventional cSCC. Immunosuppression is another risk factor for cSCC, suggesting that mycosis fungoides (MF)...